UnitedHealth to Curtail Medicare Advantage Costs: Margin Boost Ahead?

UnitedHealth (UNH) CEO Steve Hemsley issued an apology after the company's Q1 earnings miss, driven by a surge in Medicare Advantage medical costs, with the medical care ratio rising to 84.8% and expected to reach 87.8% for the year. The company suspended its full-year guidance and faces a DOJ investigation into Optum's billing practices, prompting Hemsley to pledge cost controls and transparency; despite these headwinds, Medicare Advantage membership grew 6.3% in Q1. UNH shares have declined 39.8% year-to-date amid broader industry challenges of rising benefit expenses also impacting Humana (HUM) and Elevance Health (ELV).

Analysis

UnitedHealth Group (UNH) is navigating a period of significant challenge, marked by its first earnings miss in nearly two decades for Q1 2025, primarily due to unexpectedly high medical costs within its Medicare Advantage segment, leading to a suspension of its full-year guidance. The company's medical care ratio (MCR) increased to 84.8% in Q1 2025 from 84.3% in the prior year, and is projected to climb to 87.8% for the full year 2025, a substantial rise from 85.5% in 2024. Medical costs surged 11.7% in Q1 2025 alone, following a 9.2% increase in 2024, with an anticipated growth exceeding 16% for 2025. Compounding these financial pressures is a Department of Justice investigation, reported by the Wall Street Journal, into billing practices at UNH’s Optum unit tied to its Medicare Advantage business. In response, returning CEO Steve Hemsley, who previously led UNH from 2006-2017, has issued an apology to investors and initiated a comprehensive operational review, including policies around Medicare Advantage risk adjustment and PBM, aiming to implement reforms and incorporate higher care-cost assumptions into future plan pricing. Despite these headwinds, UNH's Medicare Advantage membership grew 6.3% in Q1 2025, with a 9.2% growth expected for the full year. However, UNH's shares have significantly underperformed, declining 39.8% year-to-date compared to the industry's 29.1% fall. This challenging operating environment extends to competitors like Humana Inc. and Elevance Health, Inc., which are also experiencing rising benefit expenses; Humana saw a 6% decline in Medicare Advantage memberships in Q1, while Elevance reported an 11.8% increase in the same period.

Key Decisions for Investors

• Investors should critically monitor UnitedHealth's progress in managing its escalating medical costs and the tangible outcomes of CEO Steve Hemsley's announced operational review, particularly concerning adjustments to Medicare Advantage plan pricing and PBM strategies.
• The ongoing Department of Justice investigation into Optum's billing practices presents a material risk factor; any significant developments or findings could further impact investor sentiment and the company's financial standing.
• Given the suspension of full-year guidance, the sharp increase in projected medical costs, and the significant year-to-date share price decline of 39.8%, investors should reassess their exposure to UNH, carefully weighing the potential for a turnaround under experienced leadership against the current operational and legal headwinds.
• Consider the broader healthcare industry pressures, especially rising benefit expenses in the Medicare Advantage sector, and evaluate UNH's competitive positioning and membership growth trends relative to peers such as Elevance Health and Humana.